Evidence map›Paper›PMID 37524955›Full record

SynthesisAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2023

Efficacy of Pemafibrate Versus Fenofibrate Administration on Serum Lipid Levels in Patients with Dyslipidemia: Network Meta-Analysis and Systematic Review.

Muhammad Shayan Khan, Ghulam Mujtaba Ghumman, Abdul Baqi, Jay Shah, Muhammad Aziz, Tanveer Mir, Ayesha Tahir, Srinivas Katragadda, Hemindermeet Singh, Mohammed Taleb and 1 more

Abstract readSystematic ReviewNetwork Meta-Analysis
PubMed Publisher
In one paragraph

Synthesis in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Fibrates : Do They Still Have a Role in Therapy in 2025?Current atherosclerosis reports · 2025
    Review
  3. Review
  4. Review
  5. Role of fenofibrate in multiple sclerosis.European journal of medical research · 2024
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Muhammad Shayan KhanDepartment of Cardiology, Mercy Saint Vincent Medical Center, Toledo, OH, USA.
Ghulam Mujtaba GhummanDepartment of Internal Medicine, Mercy Saint Vincent Medical Center, Toledo, OH, USA. mujtabaghumman167@gmail.com.ORCID http://orcid.org/0000-0003-2195-106X
Abdul BaqiDepartment of Internal Medicine, Mercy Saint Vincent Medical Center, Toledo, OH, USA.
Jay ShahDepartment of Cardiology, Mercy Saint Vincent Medical Center, Toledo, OH, USA.
Muhammad AzizDepartment of Gastroenterology, University of Toledo, Toledo, OH, USA.
Tanveer MirDepartment of Internal Medicine, Detroit Medical Center, Wayne State University, Detroit, MI, USA.
Ayesha TahirDepartment of Internal Medicine, Mercy Saint Vincent Medical Center, Toledo, OH, USA.
Srinivas KatragaddaDepartment of Internal Medicine, Mercy Saint Vincent Medical Center, Toledo, OH, USA.
Hemindermeet SinghDepartment of Cardiology, Mercy Saint Vincent Medical Center, Toledo, OH, USA.
Mohammed TalebDepartment of Cardiology, Mercy Saint Vincent Medical Center, Toledo, OH, USA.
Syed Sohail AliDepartment of Cardiology, Mercy Saint Vincent Medical Center, Toledo, OH, USA.
Mercy St. Vincent Medical Center · USUniversity of Toledo · USWayne State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPemafibrate is a novel fibrate class drug that is a highly potent and selective agonist of peroxisome proliferator-activated receptor α (PPARα). We performed the first ever network meta-analysis containing the largest ever group of patients to test the efficacy of pemafibrate in improving lipid levels compared with fenofibrate and placebo in patients with dyslipidemia.

methodsPotentially relevant clinical trials were identified in Medline, PubMed, Embase, clinicaltrials.gov, and Cochrane Controlled Trials registry. Nine randomized controlled trials met the inclusion criteria out of 40 potentially available articles. The primary effect outcome was a change in the levels of triglycerides (TG), high-density lipoproteins (HDL), or low-density lipoproteins (LDL) before and after the treatment.

resultsA total of 12,359 subjects were included. The mean patient age was 54.73 (years), the mean ratio for female patients was 18.75%, and the mean examination period was 14.22 weeks. The dose for pemafibrate included in our study was 0.1, 0.2, or 0.4 mg twice daily, whereas the dose for fenofibrate was 100 mg/day. Data showed a significant reduction in TG and a mild increase in HDL levels across the pemafibrate group at different doses and fenofibrate 100 mg group (with greatest effect observed with pemafibrate 0.1 mg twice daily). A mild increase in LDL was also observed in all groups, but the increase in LDL in the 0.1 mg twice daily dose group was statistically insignificant.

conclusionPemafibrate 0.1 mg twice daily dose led to highest reduction in TG levels and the highest increase in HDL levels compared with other doses of pemafibrate, fenofibrate, and placebo.

Indexed as

DyslipidemiasFenofibrateBenzoxazolesButyratesFemaleHumansHypolipidemic AgentsMaleMiddle AgedTriglyceridesBenzoxazolesButyratesFenofibrateHypolipidemic Agents(R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acidTriglycerides

Identifiers

PMID37524955
OpenAlexW4385410022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.